Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.0%

3 terminated/withdrawn out of 15 trials

Success Rate

72.7%

-13.8% vs industry average

Late-Stage Pipeline

33%

5 trials in Phase 3/4

Results Transparency

25%

2 of 8 completed trials have results

Key Signals

2 recruiting2 with results

Enrollment Performance

Analytics

Phase 2

8(53.3%)

Phase 3

5(33.3%)

Phase 1

1(6.7%)

N/A

1(6.7%)

15Total

Phase 2(8)

Phase 3(5)

Phase 1(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials

NCT05611931Phase 3Recruiting

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Role: collaborator

NCT05581121Phase 3Recruiting

PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer

Role: collaborator

NCT03786081Phase 1Terminated

Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer

Role: collaborator

NCT03555422Phase 3Completed

Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]

Role: collaborator

NCT01244789Phase 2Active Not Recruiting

Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer

Role: collaborator

NCT04742075Phase 2Active Not Recruiting

Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer

Role: collaborator

NCT02730416Phase 2Completed

Combination Chemotherapy With Nintedanib / Placebo in Endometrial Cancer

Role: collaborator

NCT01658930Not ApplicableCompleted

Radical Versus Simple Hysterectomy and Pelvic Node Dissection With Low-risk Early Stage Cervical Cancer

Role: collaborator

NCT03598270Phase 3Completed

Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer

Role: collaborator

NCT02009579Phase 2Completed

ENGOT-cx1/BGOG-cx1: 3 Weekly Carboplatin/Paclitaxel With or Without Nintedanib in Cervix Cancer

Role: lead

NCT05201001Phase 2Withdrawn

APX005M in Patients With Recurrent Ovarian Cancer

Role: collaborator

NCT03438396Phase 2Completed

A Trial of Tisotumab Vedotin in Cervical Cancer

Role: collaborator

NCT02477644Phase 3Completed

Platine, Avastin and OLAparib in 1st Line

Role: collaborator

NCT03795272Phase 2Withdrawn

Rucaparib Maintenance Therapy in Advanced Cervical Cancer

Role: collaborator

NCT01523678Phase 2Completed

Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers

Role: lead

All 15 trials loaded